• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

(+)-和对映体(-)-CC-1065及相关试剂对序列选择性DNA烷基化的分子基础:适应富含腺嘌呤的富AT序列偏移的腺嘌呤N3烷基化选择性的烷基化位点模型。

Molecular basis for sequence selective DNA alkylation by (+)- and ent-(-)-CC-1065 and related agents: alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity.

作者信息

Boger D L, Johnson D S, Yun W, Tarby C M

机构信息

Department of Chemistry, Scripps Research Institute, La Jolla, CA 92037.

出版信息

Bioorg Med Chem. 1994 Feb;2(2):115-35. doi: 10.1016/s0968-0896(00)82007-6.

DOI:10.1016/s0968-0896(00)82007-6
PMID:7922122
Abstract

A detailed evaluation of the DNA alkylation selectivity of (+)-CC-1065, ent-(-)-CC-1065 and a series of aborted and extended analogs possessing the CPI alkylation subunit is detailed and the refinement of a model that accommodates the offset AT-rich adenine N3 alkylation selectivity of the enantiomeric agents is presented. The natural enantiomers bind in the minor groove in the 3'-->5' direction starting from the adenine N3 alkylation site across a 2 base (N-BOC-CPI; i.e. 5'-AA), 3.5 base (CPI-CDPI1/CPI-PDE-I1; i.e. 5'-AAA), 5 base (CC-1065/CPI-CDPI2; i.e. 5'-AAAAA) or 6.5 base (CPI-CDPI3; i.e. 5'-AAAAAA) AT-rich site. In contrast, the unnatural enantiomers bind in the reverse 5'-->3' direction in the minor groove and the binding site necessarily starts at the first 5' base preceding the adenine N3 alkylation site and extends across the alkylation site to the adjacent 3' bases covering an AT-rich site of 2 bases (N-BOC-CPI; e.g., 5'-AA), 5 bases (CC-1065/CPI-CDPI2; eg. 5'-AAAAA), or 6.5 bases (CPI-CDPI3; e.g. 5'-AAAAAA). Notably, the model accommodates the unusual observation that both enantiomers of N-BOC-CPI alkylate the same sites within duplex DNA (5'-AA > 5'-TA) and the required reversed binding orientation of the enantiomeric agents. The reversed binding orientation is required to permit access to the electrophilic cyclopropane and the resulting offset AT-rich alkylation selectivity is the natural consequence of the diastereomeric relationship of the adducts. Three dimensional models of the natural and unnatural enantiomer alkylations are presented which clearly illustrate the offset binding sites. A fundamentally simple model for the CC-1065 DNA alkylation reaction, that accommodates the behavior of both enantiomers, is provided in which the sequence selectivity is derived from the noncovalent binding selectivity of the agents preferentially in the narrower, sterically more accessible AT-rich minor groove, the inherent steric accessibility to the adenine N3 alkylation site that accompanies deep penetration of the agent into the minor groove within an AT-rich site, and the 2 base-pair (N-BOC-CPI), 3.5 base-pair (CPI-PDE-I1/CPI-CDPI1), 5 base-pair (CC-1065/CPI-CDPI2), or 6.5 base-pair (CPI-CDPI3) site size required to permit agent binding in the minor groove at the alkylation site.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

详细评估了(+)-CC-1065、对映体-(-)-CC-1065以及一系列具有CPI烷基化亚基的未成功和扩展类似物的DNA烷基化选择性,并提出了一个模型的改进版,该模型适用于对映体药物的富含AT的腺嘌呤N3烷基化选择性偏移。天然对映体从腺嘌呤N3烷基化位点开始,在小沟中沿3'→5'方向结合,跨越2个碱基(N-BOC-CPI;即5'-AA)、3.5个碱基(CPI-CDPI1/CPI-PDE-I1;即5'-AAA)、5个碱基(CC-1065/CPI-CDPI2;即5'-AAAAA)或6.5个碱基(CPI-CDPI3;即5'-AAAAAA)的富含AT的位点。相比之下,非天然对映体在小沟中沿相反的5'→3'方向结合,结合位点必然从腺嘌呤N3烷基化位点之前的第一个5'碱基开始,延伸穿过烷基化位点到相邻的3'碱基,覆盖2个碱基(N-BOC-CPI;例如,5'-AA)、5个碱基(CC-1065/CPI-CDPI2;例如,5'-AAAAA)或6.5个碱基(CPI-CDPI3;例如,5'-AAAAAA)的富含AT的位点。值得注意的是,该模型解释了一个不寻常的观察结果,即N-BOC-CPI的两种对映体在双链DNA内烷基化相同的位点(5'-AA > 5'-TA)以及对映体药物所需的反向结合方向。反向结合方向是为了允许亲电环丙烷接近,而产生的富含AT的烷基化选择性偏移是加合物非对映体关系的自然结果。给出了天然和非天然对映体烷基化的三维模型,清楚地说明了偏移的结合位点。提供了一个关于CC-1065 DNA烷基化反应的基本简单模型,该模型适用于两种对映体的行为,其中序列选择性源自药物在较窄、空间上更易接近的富含AT的小沟中的非共价结合选择性、药物深入富含AT位点的小沟时腺嘌呤N3烷基化位点固有的空间可及性,以及在烷基化位点允许药物在小沟中结合所需的2个碱基对(N-BOC-CPI)、3.5个碱基对(CPI-PDE-I1/CPI-CDPI1)、5个碱基对(CC-1065/CPI-CDPI2)或6.5个碱基对(CPI-CDPI3)的位点大小。(摘要截断于400字)

相似文献

1
Molecular basis for sequence selective DNA alkylation by (+)- and ent-(-)-CC-1065 and related agents: alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity.(+)-和对映体(-)-CC-1065及相关试剂对序列选择性DNA烷基化的分子基础:适应富含腺嘌呤的富AT序列偏移的腺嘌呤N3烷基化选择性的烷基化位点模型。
Bioorg Med Chem. 1994 Feb;2(2):115-35. doi: 10.1016/s0968-0896(00)82007-6.
2
Demonstration of a pronounced effect of noncovalent binding selectivity on the (+)-CC-1065 DNA alkylation and identification of the pharmacophore of the alkylation subunit.非共价结合选择性对(+)-CC-1065 DNA烷基化的显著影响的证明以及烷基化亚基药效团的鉴定。
Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1431-5. doi: 10.1073/pnas.88.4.1431.
3
Evaluation of functional analogs of CC-1065 and the duocarmycins incorporating the cross-linking 9a-chloromethyl-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-on e (C2BI) alkylation subunit.CC-1065和双环霉素功能类似物的评估,其中包含交联的9a-氯甲基-1,2,9,9a-四氢环丙[c]苯并[e]吲哚-4-酮(C2BI)烷基化亚基。
Bioorg Med Chem. 1993 Jul;1(1):27-38. doi: 10.1016/s0968-0896(00)82100-8.
4
Synthesis and evaluation of 1,2,8, 8a-Tetrahydrocyclopropa[c]pyrrolo[3,2-e]indol-4(5H)-one, the parent alkylation subunit of CC-1065 and the duocarmycins: impact of the alkylation subunit substituents and its implications for DNA alkylation catalysis.CC-1065和双环霉素的母体烷基化亚基1,2,8,8a-四氢环丙并[c]吡咯并[3,2-e]吲哚-4(5H)-酮的合成与评估:烷基化亚基取代基的影响及其对DNA烷基化催化的意义
J Org Chem. 2000 Jun 30;65(13):4101-11. doi: 10.1021/jo000297j.
5
CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents.CC-1065与双咔霉素:揭开一类新型天然衍生DNA烷基化剂的奥秘
Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3642-9. doi: 10.1073/pnas.92.9.3642.
6
CC-1065 CBI analogs: an example of enhancement of DNA alkylation efficiency through introduction of stabilizing electrostatic interactions.
Bioorg Med Chem. 1995 Jun;3(6):611-21. doi: 10.1016/0968-0896(95)00048-l.
7
Demonstration and definition of the noncovalent binding selectivity of agents related to CC-1065 by an affinity cleavage agent: noncovalent binding coincidental with alkylation.
Bioorg Med Chem. 1996 Jun;4(6):859-67. doi: 10.1016/0968-0896(96)00073-9.
8
Determination of the structural features of (+)-CC-1065 that are responsible for bending and winding of DNA.确定负责使DNA弯曲和缠绕的(+)-CC-1065的结构特征。
Chem Res Toxicol. 1991 Mar-Apr;4(2):203-13. doi: 10.1021/tx00020a013.
9
Evidence for a common molecular basis for sequence recognition of N3-guanine and N3-adenine DNA adducts involving the covalent bonding reaction of (+)-CC-1065.关于涉及(+)-CC-1065共价键合反应的N3-鸟嘌呤和N3-腺嘌呤DNA加合物序列识别的共同分子基础的证据。
Arch Pharm Res. 2002 Feb;25(1):11-24. doi: 10.1007/BF02975255.
10
CBI-CDPBO1 and CBI-CDPBI1: CC-1065 analogs containing deep-seated modifications in the DNA binding subunit.CBI-CDPBO1和CBI-CDPBI1:在DNA结合亚基中含有深层次修饰的CC-1065类似物。
Bioorg Med Chem. 1995 Jun;3(6):761-7. doi: 10.1016/0968-0896(95)00066-p.

引用本文的文献

1
Insights into Free Drug Release from Efficacious -Acyl -Aminophenol Duocarmycin Prodrugs.对有效酰基氨基酚多卡霉素前药的游离药物释放的见解。
ACS Chem Biol. 2025 Feb 21;20(2):442-454. doi: 10.1021/acschembio.4c00754. Epub 2025 Feb 9.
2
Duocarmycin SA Reduces Proliferation and Increases Apoptosis in Acute Myeloid Leukemia Cells In Vitro.多卡霉素SA体外降低急性髓系白血病细胞的增殖并增加其凋亡。
Int J Mol Sci. 2024 Apr 14;25(8):4342. doi: 10.3390/ijms25084342.
3
Cyclic Dichalcogenides Extend the Reach of Bioreductive Prodrugs to Harness Thiol/Disulfide Oxidoreductases: Applications to -Duocarmycins Targeting the Thioredoxin System.
环状二硫属化物拓展了生物还原前药对硫醇/二硫键氧化还原酶的作用范围:靶向硫氧还蛋白系统的双炔霉素的应用。
ACS Cent Sci. 2023 Mar 28;9(4):763-776. doi: 10.1021/acscentsci.2c01465. eCollection 2023 Apr 26.
4
Inverse Electron Demand Diels-Alder Reactions of Heterocyclic Azadienes, 1-Aza-1,3-Butadienes, Cyclopropenone Ketals, and Related Systems. A Retrospective.杂环氮杂双烯、1-氮杂-1,3-丁二烯、环丙烯酮缩酮及相关体系的反电子需求 Diels-Alder 反应:回顾。
J Org Chem. 2019 Aug 2;84(15):9397-9445. doi: 10.1021/acs.joc.9b00834. Epub 2019 May 23.
5
The Difference a Single Atom Can Make: Synthesis and Design at the Chemistry-Biology Interface.单原子的差异:化学-生物学界面的合成与设计。
J Org Chem. 2017 Dec 1;82(23):11961-11980. doi: 10.1021/acs.joc.7b02088. Epub 2017 Oct 13.
6
Synthesis and evaluation of duocarmycin SA analogs incorporating the methyl 1,2,8,8a-tetrahydrocyclopropa[c]imidazolo[4,5-e]indol-4-one-6-carboxylate (CImI) alkylation subunit.包含甲基1,2,8,8a-四氢环丙基[c]咪唑并[4,5-e]吲哚-4-酮-6-羧酸酯(CImI)烷基化亚基的多卡霉素SA类似物的合成与评价。
Bioorg Med Chem. 2016 Oct 15;24(20):4779-4786. doi: 10.1016/j.bmc.2016.04.050. Epub 2016 Apr 26.
7
A five-membered lactone prodrug of CBI-based analogs of the duocarmycins.多卡霉素基于CBI类似物的五元内酯前药。
Tetrahedron Lett. 2015 Jun 3;56(23):3101-3104. doi: 10.1016/j.tetlet.2014.11.038.
8
Asymmetric synthesis of a CBI-based cyclic N-acyl O-amino phenol duocarmycin prodrug.一种基于CBI的环状N-酰基O-氨基苯酚多卡霉素前药的不对称合成。
J Org Chem. 2014 Oct 17;79(20):9699-703. doi: 10.1021/jo501839x. Epub 2014 Oct 3.
9
A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding.疏水性性质与 DNA 烷化抗肿瘤药物双氰胺类生物活性之间的基本关系:疏水结合驱动键合。
J Med Chem. 2013 Sep 12;56(17):6845-57. doi: 10.1021/jm400665c. Epub 2013 Aug 29.
10
Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers.评估还原激活型 duocarmycin 前药对鼠类和人类实体瘤的作用。
Cancer Biol Ther. 2013 Jun;14(6):527-36. doi: 10.4161/cbt.24348.